Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15185814 | 1.00 | PAOX (0.62) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL12444633 | 0.93 | PAOX (0.69) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL5693542 | 0.90 | KDM4E (0.61) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL13588485 | 0.87 | PAOX (0.49) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL27160328 | 0.87 | PAOX (0.60) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL19140763 | 0.83 | PAOX (0.66) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL15185827 | 0.82 | SMN1; SMN2 (0.55) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL18947953 | 0.82 | HPGD (0.53) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL14289054 | 0.82 | KDM4E (0.52) | PAOXKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL21806080 | 0.82 | PAOX (0.39) | PAOXSMN1; SMN2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385369-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | GB005 INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-10562893-B2 | Benzimidazoles derivatives as Tec kinases family inhibitors | GB005, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180319781-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | GB005, INC. | 2018-11-08 | — | — | US | disclosed |
| EP-3353170-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | Pharmascience Inc. (CA) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017049401-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | PHARMASCIENCE INC. (CA) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562893-B2 | Benzimidazoles derivatives as Tec kinases family inhibitors | BMX, TEC, BTK | PAOX 2351/4885KDM4E 2460/4885MAPK1 275/4885 |
| US-20180319781-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | BMX, TEC, BTK | PAOX 2060/4885KDM4E 2473/4885MAPK1 254/4885 |
| US-20200385369-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | BMX, TEC, BTK | PAOX 2096/4885KDM4E 2440/4885MAPK1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.